<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118273</url>
  </required_header>
  <id_info>
    <org_study_id>13053</org_study_id>
    <nct_id>NCT01118273</nct_id>
  </id_info>
  <brief_title>Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine</brief_title>
  <official_title>A Double-Blind, Randomized, Pilot Study Assessing the Analgesic and Hypnotic Effect of Naproxen Sodium and Diphenhydramine Combination in Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen
      sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and
      an ibuprofen and diphenhydramine combination
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time Measured by Actigraphy</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. In calculating the total sleep time, subjects who took rescue medication were treated as &quot;awake&quot; from the time the rescue medication was given until the end of the sleep period. In addition, if subjects rescued before sleep onset, their total sleep time was set to zero.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wake After Sleep Onset (WASO) Measured by Actigraphy</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. WASO was defined as minutes of awake during the period of sleep onset and offset, where sleep onset is the first 20-minute block with 19 minutes of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Latency Measured by Actigraphy</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Sleep latency was defined as minutes to sleep onset since dosing, where sleep onset was the first 20-minute block with 19 minutes of sleep. For subjects who had not achieved sleep onset (e.g., due to taking rescue medication before achieving sleep onset), sleep latency was considered as censored at the time of wakening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Study Medication as a Sleep-aid</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 0 being poor to 4 being excellent: How would you rate the study medication you received as a sleep aid?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary - Sleep Quality</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 1 being very poor and 5 being very good: How was your sleep?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary - Calmness of Sleep</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 1 being very restless and 5 being very calm: How calm was your sleep?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary - Easiness to Fall Asleep</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 1 being very difficult to 5 being very easy: How easy was it to fall asleep?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary - Premature Awakening</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 1 being woke up much too early to 3 being no: Premature awakening?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary - Ease of Awakening</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 1 being very difficult to 5 being very easy: Ease of awakening?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary - Well Rested</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 1 being not rested at all to 3 being completely rested: Well-rested?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary - Sufficient Sleep</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject rating of following question with 1 being no, definitely too little to 5 being yes, definitely enough: Did you get enough (sufficient) sleep?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time by Subject Assessment</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject responded to: Please estimate the number of hours and minutes you think that you slept.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Index</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Sleep Quality Index is the mean score of items, 'sleep quality', 'calm sleep', 'ease falling asleep', and 'slept throughout' on the Karolinska Sleep Diary, ranges from 1 (worst possible) to 5 (best possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Rating of Severity in Categorical Pain Rating Scale Score</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject responded to question, 'My pain at this time is' by selecting one of the following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Categorical Pain Rating Scale Score</measure>
    <time_frame>Baseline and up to 10 hours</time_frame>
    <description>Subjects responded to question, 'My pain at this time is' with following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3). Subjects completed this question at baseline (post-dental surgery) and after sleep period. The following measure is the change in pain rating from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Rating of Severity in Visual Analog Scale (VAS) Score</measure>
    <time_frame>At 10 hours</time_frame>
    <description>Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Analog Scale (VAS) Score</measure>
    <time_frame>Baseline and up to 10 hours</time_frame>
    <description>Subjects completed the VAS scale at baseline (post-dental surgery) and after completion of the sleep period. Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.This measure indicates the change in pain severity rating on the VAS scale from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Rating of Pain Relief</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subjects responded to question, &quot;Overall, the relief from my starting pain was&quot; by checking one of the following choices: no relief (0), a little relief (1), some relief (2), a lot of relief (3), complete relief (4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Rescue Medication</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the time to taking rescue medication from the time the subject took study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Proportion of Participants Taking Rescue Medication by Hour</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the proportion of subjects who rescued in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Study Medication as a Pain Reliever</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subject responded to question, 'How would you rating this study medication you received as a pain-reliever?' with the following choices: Poor (0), Fair(1), Good(2), Very Good(3), Excellent(4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Times Participants Took Rescue Medication</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the number of times rescue medication was taken by a subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Wake Time Measured by Actigraphy</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency Measured by Actigraphy</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity Mean Measured by Actigraphy</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Activity mean - average movement per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake Episode Measured by Actigraphy</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Wake Episodes - # of blocks of continuous wake epochs (defined as 2 or more consecutive epochs scored as wake that ends when there is at least one epoch scored as sleep subsequent to the start of the wake epochs).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen Sodium 440 mg (BAYH6689)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen Sodium 220 mg (BAYH6689)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DPH 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 400 mg / Diphenhydramine citrate 76 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</intervention_name>
    <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
    <arm_group_label>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium 440 mg (BAYH6689)</intervention_name>
    <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
    <arm_group_label>Naproxen Sodium 440 mg (BAYH6689)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</intervention_name>
    <description>One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg</description>
    <arm_group_label>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium 220 mg (BAYH6689)</intervention_name>
    <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
    <arm_group_label>Naproxen Sodium 220 mg (BAYH6689)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPH 50mg</intervention_name>
    <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
    <arm_group_label>DPH 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 400 mg / Diphenhydramine citrate 76 mg</intervention_name>
    <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
    <arm_group_label>Ibuprofen 400 mg / Diphenhydramine citrate 76 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, ambulatory, male and female volunteers between 16-45 years of age;

          -  Scheduled to undergo surgical removal of 1 to 3 impacted third molars, one of which
             must be at least a partial bony mandibular impaction;

          -  Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a
             score of &gt;/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale by 2030 h
             +/- 15 minutes on the day of surgery;

          -  Female subjects of childbearing potential must be using a medically acceptable form of
             birth control for at least 1 month prior to screening (3 months on oral
             contraceptives), e.g. oral or patch contraceptives, intrauterine device, Depo-Provera,
             or double-barrier and have a negative pregnancy test at Screening and prior to
             surgery. Female subjects of nonchildbearing potential must be amenorrheic for at least
             2 years or had a hysterectomy and/or bilateral oophorectomy;

          -  Provide a personally signed and dated informed consent indicating that the subject has
             been informed of all pertinent aspects of the trial, (subjects &lt;18 years of age must
             sign a written assent and have parental or guardian consent).

        Exclusion Criteria:

          -  History of hypersensitivity to naproxen, diphenhydramine, nonsteroidal
             antiinflammatory drugs (NSAIDS), tramadol, aspirin or any other antihistamine and
             similar pharmacological agents or components of the products;

          -  Evidence or history of clinically significant (in the judgment of the investigator)
             hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,
             psychiatric, neurologic diseases, or malignancies within the last 5 years;

          -  Relevant concomitant disease such as asthma (exercise induced asthma is permitted),
             chronic sinusitis or nasal structural abnormalities causing greater than 50 percent
             obstruction (polyposis nasi, marked septal deviation) that can interfere with the
             conduct of the study in the judgment of the investigator;

          -  Current or past history of bleeding disorder(s);

          -  Acute illness or local infection prior to surgery that can interfere with the conduct
             of the study in the judgment of the investigator;

          -  Chronic use of antihistamines defined as using 5 or more times a week for 2 or more
             consecutive weeks during the past 3 months;

          -  Positive alcohol breathalyzer test and negative urine drug test prior to surgery;

          -  Females who are pregnant or lactating;

          -  Chronic or severe sleep problems that do not respond to Over the counter (OTC)
             medication and requires a prescription hypnotic or sedative;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <disposition_first_submitted>May 30, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 30, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 5, 2012</disposition_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naproxen sodium</keyword>
  <keyword>Diphenhydramine</keyword>
  <keyword>Drugs, Investigational</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
          <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
        </group>
        <group group_id="P2">
          <title>Naproxen Sodium 440 mg (BAYH6689)</title>
          <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="P3">
          <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
          <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
        </group>
        <group group_id="P4">
          <title>Naproxen Sodium 220 mg (BAYH6689)</title>
          <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="P5">
          <title>DPH 50mg</title>
          <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="P6">
          <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
          <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
          <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
        </group>
        <group group_id="B2">
          <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
          <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
        </group>
        <group group_id="B3">
          <title>Naproxen Sodium 220 mg (BAYH6689)</title>
          <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="B4">
          <title>DPH 50mg</title>
          <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="B5">
          <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
          <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
        </group>
        <group group_id="B6">
          <title>Naproxen Sodium 440 mg (BAYH6689)</title>
          <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="27"/>
            <count group_id="B6" value="27"/>
            <count group_id="B7" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" spread="2.8"/>
                    <measurement group_id="B2" value="20" spread="2.8"/>
                    <measurement group_id="B3" value="19" spread="2.0"/>
                    <measurement group_id="B4" value="19" spread="3.0"/>
                    <measurement group_id="B5" value="19" spread="2.5"/>
                    <measurement group_id="B6" value="20" spread="2.6"/>
                    <measurement group_id="B7" value="19" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Categorical Pain Rating Scale</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Sleep Time Measured by Actigraphy</title>
        <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. In calculating the total sleep time, subjects who took rescue medication were treated as “awake” from the time the rescue medication was given until the end of the sleep period. In addition, if subjects rescued before sleep onset, their total sleep time was set to zero.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time Measured by Actigraphy</title>
          <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. In calculating the total sleep time, subjects who took rescue medication were treated as “awake” from the time the rescue medication was given until the end of the sleep period. In addition, if subjects rescued before sleep onset, their total sleep time was set to zero.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.80" lower_limit="259" upper_limit="420"/>
                    <measurement group_id="O2" value="304.60" lower_limit="224" upper_limit="385"/>
                    <measurement group_id="O3" value="413.89" lower_limit="333" upper_limit="494"/>
                    <measurement group_id="O4" value="308.89" lower_limit="228" upper_limit="389"/>
                    <measurement group_id="O5" value="76.35" lower_limit="-4" upper_limit="157"/>
                    <measurement group_id="O6" value="335.68" lower_limit="254" upper_limit="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wake After Sleep Onset (WASO) Measured by Actigraphy</title>
        <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. WASO was defined as minutes of awake during the period of sleep onset and offset, where sleep onset is the first 20-minute block with 19 minutes of sleep.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Wake After Sleep Onset (WASO) Measured by Actigraphy</title>
          <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. WASO was defined as minutes of awake during the period of sleep onset and offset, where sleep onset is the first 20-minute block with 19 minutes of sleep.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.96" lower_limit="70" upper_limit="210"/>
                    <measurement group_id="O2" value="190.91" lower_limit="121" upper_limit="261"/>
                    <measurement group_id="O3" value="75.66" lower_limit="7" upper_limit="144"/>
                    <measurement group_id="O4" value="145.67" lower_limit="72" upper_limit="219"/>
                    <measurement group_id="O5" value="428.34" lower_limit="351" upper_limit="506"/>
                    <measurement group_id="O6" value="129.02" lower_limit="59" upper_limit="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Latency Measured by Actigraphy</title>
        <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Sleep latency was defined as minutes to sleep onset since dosing, where sleep onset was the first 20-minute block with 19 minutes of sleep. For subjects who had not achieved sleep onset (e.g., due to taking rescue medication before achieving sleep onset), sleep latency was considered as censored at the time of wakening.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Latency Measured by Actigraphy</title>
          <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Sleep latency was defined as minutes to sleep onset since dosing, where sleep onset was the first 20-minute block with 19 minutes of sleep. For subjects who had not achieved sleep onset (e.g., due to taking rescue medication before achieving sleep onset), sleep latency was considered as censored at the time of wakening.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.17" lower_limit="9" upper_limit="50"/>
                    <measurement group_id="O2" value="32.81" lower_limit="12" upper_limit="53"/>
                    <measurement group_id="O3" value="46.77" lower_limit="27" upper_limit="67"/>
                    <measurement group_id="O4" value="31.58" lower_limit="10" upper_limit="53"/>
                    <measurement group_id="O5" value="41.05" lower_limit="18" upper_limit="64"/>
                    <measurement group_id="O6" value="36.38" lower_limit="16" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Study Medication as a Sleep-aid</title>
        <description>Subject rating of following question with 0 being poor to 4 being excellent: How would you rate the study medication you received as a sleep aid?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Study Medication as a Sleep-aid</title>
          <description>Subject rating of following question with 0 being poor to 4 being excellent: How would you rate the study medication you received as a sleep aid?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleep Diary - Sleep Quality</title>
        <description>Subject rating of following question with 1 being very poor and 5 being very good: How was your sleep?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleep Diary - Sleep Quality</title>
          <description>Subject rating of following question with 1 being very poor and 5 being very good: How was your sleep?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = Rather poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = Neither poor nor good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = Rather good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 = Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleep Diary - Calmness of Sleep</title>
        <description>Subject rating of following question with 1 being very restless and 5 being very calm: How calm was your sleep?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleep Diary - Calmness of Sleep</title>
          <description>Subject rating of following question with 1 being very restless and 5 being very calm: How calm was your sleep?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = Very restless</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = Rather restless</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = Neither restless nor calm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = Rather calm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 = Very calm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleep Diary - Easiness to Fall Asleep</title>
        <description>Subject rating of following question with 1 being very difficult to 5 being very easy: How easy was it to fall asleep?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleep Diary - Easiness to Fall Asleep</title>
          <description>Subject rating of following question with 1 being very difficult to 5 being very easy: How easy was it to fall asleep?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = Rather difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = Neither difficult nor easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = Rather easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 = Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleep Diary - Premature Awakening</title>
        <description>Subject rating of following question with 1 being woke up much too early to 3 being no: Premature awakening?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleep Diary - Premature Awakening</title>
          <description>Subject rating of following question with 1 being woke up much too early to 3 being no: Premature awakening?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = Woke up much too early</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = Woke up somewhat too early</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleep Diary - Ease of Awakening</title>
        <description>Subject rating of following question with 1 being very difficult to 5 being very easy: Ease of awakening?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleep Diary - Ease of Awakening</title>
          <description>Subject rating of following question with 1 being very difficult to 5 being very easy: Ease of awakening?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = Rather difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = Neither difficult nor easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = Rather easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 = Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleep Diary - Well Rested</title>
        <description>Subject rating of following question with 1 being not rested at all to 3 being completely rested: Well-rested?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleep Diary - Well Rested</title>
          <description>Subject rating of following question with 1 being not rested at all to 3 being completely rested: Well-rested?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = Not rested at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = Somewhat unrested</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = Completely rested</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleep Diary - Sufficient Sleep</title>
        <description>Subject rating of following question with 1 being no, definitely too little to 5 being yes, definitely enough: Did you get enough (sufficient) sleep?</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleep Diary - Sufficient Sleep</title>
          <description>Subject rating of following question with 1 being no, definitely too little to 5 being yes, definitely enough: Did you get enough (sufficient) sleep?</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = No, definitely too little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = No, much too little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = No, somewhat too little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = Yes, almost enough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 = Yes, definitely enough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sleep Time by Subject Assessment</title>
        <description>Subject responded to: Please estimate the number of hours and minutes you think that you slept.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time by Subject Assessment</title>
          <description>Subject responded to: Please estimate the number of hours and minutes you think that you slept.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.32" lower_limit="231" upper_limit="381"/>
                    <measurement group_id="O2" value="309.97" lower_limit="235" upper_limit="385"/>
                    <measurement group_id="O3" value="339.08" lower_limit="264" upper_limit="414"/>
                    <measurement group_id="O4" value="309.23" lower_limit="234" upper_limit="384"/>
                    <measurement group_id="O5" value="160.49" lower_limit="85" upper_limit="236"/>
                    <measurement group_id="O6" value="299.58" lower_limit="223" upper_limit="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality Index</title>
        <description>Sleep Quality Index is the mean score of items, 'sleep quality', 'calm sleep', 'ease falling asleep', and 'slept throughout' on the Karolinska Sleep Diary, ranges from 1 (worst possible) to 5 (best possible).</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population with available data (missing values were not imputed).</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality Index</title>
          <description>Sleep Quality Index is the mean score of items, 'sleep quality', 'calm sleep', 'ease falling asleep', and 'slept throughout' on the Karolinska Sleep Diary, ranges from 1 (worst possible) to 5 (best possible).</description>
          <population>ITT (Intent to Treat) Population with available data (missing values were not imputed).</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" lower_limit="3.1" upper_limit="3.9"/>
                    <measurement group_id="O2" value="2.89" lower_limit="2.5" upper_limit="3.3"/>
                    <measurement group_id="O3" value="3.40" lower_limit="3.0" upper_limit="3.8"/>
                    <measurement group_id="O4" value="3.12" lower_limit="2.7" upper_limit="3.5"/>
                    <measurement group_id="O5" value="2.96" lower_limit="2.6" upper_limit="3.4"/>
                    <measurement group_id="O6" value="3.37" lower_limit="3.0" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating of Severity in Categorical Pain Rating Scale Score</title>
        <description>Subject responded to question, 'My pain at this time is' by selecting one of the following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3).</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rating of Severity in Categorical Pain Rating Scale Score</title>
          <description>Subject responded to question, 'My pain at this time is' by selecting one of the following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3).</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.51"/>
                    <measurement group_id="O2" value="2.48" spread="0.51"/>
                    <measurement group_id="O3" value="2.48" spread="0.51"/>
                    <measurement group_id="O4" value="2.48" spread="0.51"/>
                    <measurement group_id="O5" value="2.37" spread="0.49"/>
                    <measurement group_id="O6" value="2.22" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="1.02"/>
                    <measurement group_id="O2" value="1.48" spread="1.05"/>
                    <measurement group_id="O3" value="1.26" spread="0.94"/>
                    <measurement group_id="O4" value="1.78" spread="0.97"/>
                    <measurement group_id="O5" value="2.67" spread="0.62"/>
                    <measurement group_id="O6" value="1.41" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Categorical Pain Rating Scale Score</title>
        <description>Subjects responded to question, 'My pain at this time is' with following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3). Subjects completed this question at baseline (post-dental surgery) and after sleep period. The following measure is the change in pain rating from baseline.</description>
        <time_frame>Baseline and up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Categorical Pain Rating Scale Score</title>
          <description>Subjects responded to question, 'My pain at this time is' with following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3). Subjects completed this question at baseline (post-dental surgery) and after sleep period. The following measure is the change in pain rating from baseline.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-1.5" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-1.3" upper_limit="-0.6"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-1.5" upper_limit="-0.8"/>
                    <measurement group_id="O4" value="-0.7" lower_limit="-1.0" upper_limit="-0.3"/>
                    <measurement group_id="O5" value="0.3" lower_limit="-0.1" upper_limit="0.6"/>
                    <measurement group_id="O6" value="-0.9" lower_limit="-1.3" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating of Severity in Visual Analog Scale (VAS) Score</title>
        <description>Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.</description>
        <time_frame>At 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rating of Severity in Visual Analog Scale (VAS) Score</title>
          <description>Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.11" spread="11.6"/>
                    <measurement group_id="O2" value="77.26" spread="13.1"/>
                    <measurement group_id="O3" value="78.19" spread="13.4"/>
                    <measurement group_id="O4" value="73.70" spread="12.3"/>
                    <measurement group_id="O5" value="79.15" spread="9.76"/>
                    <measurement group_id="O6" value="73.11" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.11" spread="31.1"/>
                    <measurement group_id="O2" value="40.30" spread="33.0"/>
                    <measurement group_id="O3" value="30.33" spread="28.6"/>
                    <measurement group_id="O4" value="48.59" spread="33.4"/>
                    <measurement group_id="O5" value="84.26" spread="19.9"/>
                    <measurement group_id="O6" value="38.19" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Analog Scale (VAS) Score</title>
        <description>Subjects completed the VAS scale at baseline (post-dental surgery) and after completion of the sleep period. Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.This measure indicates the change in pain severity rating on the VAS scale from baseline.</description>
        <time_frame>Baseline and up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Analog Scale (VAS) Score</title>
          <description>Subjects completed the VAS scale at baseline (post-dental surgery) and after completion of the sleep period. Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.This measure indicates the change in pain severity rating on the VAS scale from baseline.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.04" lower_limit="-55.1" upper_limit="-33.0"/>
                    <measurement group_id="O2" value="-36.65" lower_limit="-47.7" upper_limit="-25.6"/>
                    <measurement group_id="O3" value="-47.26" lower_limit="-58.4" upper_limit="-36.2"/>
                    <measurement group_id="O4" value="-25.89" lower_limit="-37.0" upper_limit="-14.8"/>
                    <measurement group_id="O5" value="6.00" lower_limit="-5.1" upper_limit="17.1"/>
                    <measurement group_id="O6" value="-35.89" lower_limit="-47.0" upper_limit="-24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating of Pain Relief</title>
        <description>Subjects responded to question, &quot;Overall, the relief from my starting pain was&quot; by checking one of the following choices: no relief (0), a little relief (1), some relief (2), a lot of relief (3), complete relief (4).</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rating of Pain Relief</title>
          <description>Subjects responded to question, &quot;Overall, the relief from my starting pain was&quot; by checking one of the following choices: no relief (0), a little relief (1), some relief (2), a lot of relief (3), complete relief (4).</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A lot relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Rescue Medication</title>
        <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the time to taking rescue medication from the time the subject took study treatment.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Rescue Medication</title>
          <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the time to taking rescue medication from the time the subject took study treatment.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Technically the data is not computable due to insufficient number of events</measurement>
                    <measurement group_id="O2" value="NA">Technically the data is not computable due to insufficient number of events</measurement>
                    <measurement group_id="O3" value="NA">Technically the data is not computable due to insufficient number of events</measurement>
                    <measurement group_id="O4" value="NA">Technically the data is not computable due to insufficient number of events</measurement>
                    <measurement group_id="O5" value="NA">Technically the data is not computable due to insufficient number of events</measurement>
                    <measurement group_id="O6" value="NA">Technically the data is not computable due to insufficient number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Proportion of Participants Taking Rescue Medication by Hour</title>
        <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the proportion of subjects who rescued in the study.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Proportion of Participants Taking Rescue Medication by Hour</title>
          <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the proportion of subjects who rescued in the study.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Study Medication as a Pain Reliever</title>
        <description>Subject responded to question, 'How would you rating this study medication you received as a pain-reliever?' with the following choices: Poor (0), Fair(1), Good(2), Very Good(3), Excellent(4)</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Study Medication as a Pain Reliever</title>
          <description>Subject responded to question, 'How would you rating this study medication you received as a pain-reliever?' with the following choices: Poor (0), Fair(1), Good(2), Very Good(3), Excellent(4)</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Times Participants Took Rescue Medication</title>
        <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the number of times rescue medication was taken by a subject.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Times Participants Took Rescue Medication</title>
          <description>Subjects were allowed to &quot;rescue&quot; and take a non-study pain reliever if the pain was not tolerable. This measure represents for the number of times rescue medication was taken by a subject.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Wake Time Measured by Actigraphy</title>
        <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Wake Time Measured by Actigraphy</title>
          <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.72" lower_limit="174" upper_limit="333"/>
                    <measurement group_id="O2" value="290.03" lower_limit="210" upper_limit="370"/>
                    <measurement group_id="O3" value="180.21" lower_limit="100" upper_limit="260"/>
                    <measurement group_id="O4" value="285.62" lower_limit="206" upper_limit="365"/>
                    <measurement group_id="O5" value="518.58" lower_limit="439" upper_limit="598"/>
                    <measurement group_id="O6" value="255.20" lower_limit="175" upper_limit="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Efficiency Measured by Actigraphy</title>
        <description>Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency Measured by Actigraphy</title>
          <description>Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Percentage of sleep time</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.24" lower_limit="44" upper_limit="71"/>
                    <measurement group_id="O2" value="51.49" lower_limit="38" upper_limit="65"/>
                    <measurement group_id="O3" value="68.87" lower_limit="55" upper_limit="82"/>
                    <measurement group_id="O4" value="52.09" lower_limit="39" upper_limit="66"/>
                    <measurement group_id="O5" value="12.85" lower_limit="-1" upper_limit="26"/>
                    <measurement group_id="O6" value="56.70" lower_limit="43" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activity Mean Measured by Actigraphy</title>
        <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Activity mean - average movement per minute.</description>
        <time_frame>Up to 10 hours</time_frame>
        <population>ITT (Intent to Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity Mean Measured by Actigraphy</title>
          <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Activity mean - average movement per minute.</description>
          <population>ITT (Intent to Treat) Population</population>
          <units>Movement per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.09" lower_limit="25" upper_limit="59"/>
                    <measurement group_id="O2" value="48.48" lower_limit="32" upper_limit="65"/>
                    <measurement group_id="O3" value="26.73" lower_limit="10" upper_limit="43"/>
                    <measurement group_id="O4" value="52.36" lower_limit="36" upper_limit="69"/>
                    <measurement group_id="O5" value="72.43" lower_limit="56" upper_limit="89"/>
                    <measurement group_id="O6" value="41.14" lower_limit="24" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wake Episode Measured by Actigraphy</title>
        <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Wake Episodes - # of blocks of continuous wake epochs (defined as 2 or more consecutive epochs scored as wake that ends when there is at least one epoch scored as sleep subsequent to the start of the wake epochs).</description>
        <time_frame>Up to 10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
          </group>
          <group group_id="O2">
            <title>Naproxen Sodium 440 mg (BAYH6689)</title>
            <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
          </group>
          <group group_id="O4">
            <title>Naproxen Sodium 220 mg (BAYH6689)</title>
            <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O5">
            <title>DPH 50mg</title>
            <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
          </group>
          <group group_id="O6">
            <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
            <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Wake Episode Measured by Actigraphy</title>
          <description>Actigraphy is a non-intrusive tool that measures an individual’s movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Wake Episodes - # of blocks of continuous wake epochs (defined as 2 or more consecutive epochs scored as wake that ends when there is at least one epoch scored as sleep subsequent to the start of the wake epochs).</description>
          <units>Wake episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.38" lower_limit="5" upper_limit="11"/>
                    <measurement group_id="O2" value="10.86" lower_limit="8" upper_limit="14"/>
                    <measurement group_id="O3" value="13.26" lower_limit="10" upper_limit="16"/>
                    <measurement group_id="O4" value="9.89" lower_limit="7" upper_limit="13"/>
                    <measurement group_id="O5" value="5.84" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="O6" value="11.98" lower_limit="9" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events (TEAEs) were collected after the administration of the first dose of study drug up to 5 days post drug administration, or up to 30 days after the last study drug administration if they were serious adverse events (SAEs).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg</title>
          <description>Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.</description>
        </group>
        <group group_id="E2">
          <title>Naproxen Sodium 440 mg (BAYH6689)</title>
          <description>Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="E3">
          <title>Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg</title>
          <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 1 tablet of placebo, single dose, orally.</description>
        </group>
        <group group_id="E4">
          <title>Naproxen Sodium 220 mg (BAYH6689)</title>
          <description>Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="E5">
          <title>DPH 50mg</title>
          <description>Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.</description>
        </group>
        <group group_id="E6">
          <title>Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg</title>
          <description>Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>RESTLESS LEGS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

